Cardiac Monitoring And Cardiac Rhythm Management Devices Market (2026 - 2033) Size, Share & Trends Analysis Report By Product (Cardiac Monitoring Devices, Cardiac Rhythm Management Devices), By End Use (Hospitals, Ambulatory Surgery Centers), By Region, And Segment Forecasts

Cardiac Monitoring And Cardiac Rhythm Management Devices Market Summary

The growing adoption of advanced cardiac monitoring solutions, such as wearable ECG devices, implantable loop recorders, and remote monitoring platforms, is enabling earlier diagnosis and continuous disease management outside of hospital settings. The technological advancements in CRM devices, including leadless and MRI-compatible pacemakers and next-generation ICDs, are enhancing clinical outcomes and device longevity, thereby supporting replacement demand and promoting broader adoption.

Increasing cardiovascular incidence is one of the key factors driving the growth of the cardiac monitoring and cardiac rhythm management industry. According to an Oxford Academic article published in January 2025, the global age-standardized prevalence of cardiovascular disease reaches approximately 7,179 cases per 100,000 people, highlighting the significant and ongoing impact of heart conditions worldwide. Such widespread prevalence means that millions are living with diseases that require careful monitoring and timely intervention to prevent complications. In September 2025, Philips introduced a new telemetry platform featuring the Telemetry Monitor 5500 to streamline cardiac monitoring and reduce non-actionable alarms. The system supports scalable, wearable monitoring, mobile workflows, and up to 30-day post-discharge cardiac tracking through its MCOT service.

Increasing awareness campaigns and government-initiated screening programs for early detection of CVDs contribute to market expansion by ensuring more patients receive timely diagnosis and treatment. According to an article published by Hearst Newspapers II, LLC in June 2025, Midland Memorial Hospital, in collaboration with the Championship Hearts Foundation, offers free ECG and limited echocardiogram screenings to teenagers between 14 and 18 years old. In previous events, these screenings identified severe, potentially life-threatening heart conditions, such as hypertrophic cardiomyopathy, in approximately 1 out of every 250 participants. Initiatives like this highlight the critical role of early detection in preventing sudden cardiac events among young people. They also emphasize the growing need for portable ECG devices and advanced rhythm-monitoring technologies tailored for pediatric and adolescent populations, thereby contributing to the market expansion.

Moreover, according to the American Heart Association, Inc. article published in November 2023, the 2023 guidelines released by the American Heart Association (AHA), American College of Cardiology (ACC), American College of Chest Physicians (ACCP), and the Heart Rhythm Society (HRS) highlight the importance of raising awareness and incorporating routine screening for atrial fibrillation (AFib), especially in high-risk groups such as older adults. These recommendations encourage regular pulse and ECG screenings to support early diagnosis and effective treatment. Detecting and managing AFib promptly is crucial because it can significantly lower the risk of stroke and other serious health issues. This emphasis on proactive screening and education contributes to an increased demand for cardiac monitoring and rhythm management devices, which play a central role in identifying heart rhythm disorders and guiding appropriate medical care, thereby driving the market growth.

The efficiency of targeted screening programs for CVDs fuels market growth. According to Springer Nature in June 2024, a review of cardiology reports that examines the impact of screening programs highlights findings from multicenter studies, such as AF-SCREEN and STROKESTOP, which demonstrate that targeted screening significantly enhances the detection of CVDs, particularly among older adults. The review strongly supports establishing national screening initiatives to address the growing burden of AFib-related complications, highlighting the critical role of early detection and intervention.

The technologically advanced products offered by the key players drive the market's growth. For instance, in April 2025, LifeSignals, Inc., introduced the UbiqVue 2AYe Holter System at Heart Rhythm 2025. This new Holter monitoring solution, distributed in collaboration with UltraLinQ Healthcare Solutions, is designed to streamline cardiac monitoring workflows by producing diagnostic reports far faster than traditional methods and eliminating the need to mail or physically retrieve the biosensor device.

At the heart of the UbiqVue system is the 2AYe Biosensora, a disposable, chest-worn device capable of continuously recording two-channel ECG and event data for up to five days. Data collected by the biosensor is securely encrypted and sent via a patient-facing mobile app to a cloud-based platform during the monitoring period. Once the Holter test concludes, the patient’s data is quickly analyzed through cloud-based ECG analytics, substantially reducing the review time required by certified cardiac technicians and enabling physicians to access finalized reports within hours.

Comparison Of Cardiac Monitoring And Rhythm Management Devices

Data Connectivity In Cardiac Monitoring And Rhythm Management

Modern cardiac monitoring and rhythm management devices rely on advanced data connectivity to enable remote, real-time patient monitoring and seamless clinical workflows. These devices transmit vital signs and electrocardiogram (ECG) data through secure channels such as Wi-Fi, Bluetooth, or cellular networks to cloud-based platforms. Healthcare providers can access patient data via web portals, mobile apps, or integrated hospital systems, enabling timely intervention and longitudinal tracking. Data connectivity also supports integration with electronic health records (EHRs) and third-party analytics platforms, ensuring compliance with security and privacy standards, including HIPAA, GDPR, and regional regulations. This connectivity enhances workflow efficiency, patient adherence, and clinical decision-making while supporting large-scale population health initiatives.

Connectivity Features For Cardiac Monitoring And Cardiac Rhythm Management

Market Concentration & Characteristics

The global cardiac monitoring and cardiac rhythm management devices market is characterized by a high degree of innovation, driven by the development of technologically advanced solutions and continuous advancements in pacemaker technology. For instance, in March 2025, MicroPort Scientific Corporation launched the localized TEN pacemaker family in China through its affiliate MicroPort CRM Shanghai. The TEN series includes six compact, long-life models across T, E, and N categories, offering AutoMRI compatibility and the SAM function for continuous sleep and arrhythmia monitoring.

Several market players, including Stryker, Abbott, Boston Scientific Corporation, and Medtronic, actively engage in mergers and acquisitions within the market. Through these activities, companies pursue key strategies including developing innovative products, forming strategic partnerships, and expanding into new geographic regions. For example, in December 2025, Teleflex Incorporated announced that it had entered into a definitive agreement to acquire substantially all of BIOTRONIK SE & Co. KG's Vascular Intervention business for an estimated cash payment of approximately €760 million (approximately USD 839.04 million).

Regulatory oversight significantly aligns the cardiac monitoring and cardiac rhythm management industry. Strict evaluation criteria from agencies such as the FDA and EMA ensure that devices meet high standards of patient safety and therapeutic effectiveness, often extending development timelines and approval costs. Nevertheless, evolving regulatory pathways, including expedited review programs and digital health frameworks, enable the faster clearance of innovative technologies such as wearable monitors, implantable loop recorders, and next-generation cardiac rhythm devices. These regulatory shifts enable manufacturers to deliver advanced, patient-centric solutions while maintaining rigorous safety and performance standards.

There are currently no direct substitutes. These systems play a crucial role in continuous heart rhythm assessment, the early detection of abnormalities, and the timely implementation of therapeutic interventions. Tools such as standard ECGs or periodic check-ups help identify cardiac issues; however lack the continuous, high-fidelity monitoring and therapeutic capabilities offered by implantable devices, wearable sensors, and advanced rhythm management solutions. As such, their unique ability to combine diagnostic precision with real-time management remains essential in modern cardiac care.

Key manufacturers in the cardiac monitoring and cardiac rhythm management industry are actively expanding their reach by exploring untapped regional markets, collaborating with local distribution partners, and tailoring their product portfolios to meet the distinct healthcare needs of various geographies. In December 2025, Ventripoint partnered with the Nisga’a Valley Health Authority to launch a hub-and-spoke model utilizing its AI-powered VMS+ ultrasound technology, delivering advanced cardiac imaging to remote and Indigenous communities in British Columbia.

Product Insights

The cardiac rhythm management devices segment dominated the market with the largest revenue share of 73.61% in 2025. Cardiac rhythm management (CRM) devices are designed to regulate heart rhythm in patients with arrhythmias, bradycardia, or heart failure. This segment encompasses implantable devices, including pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) systems. These devices restore usual cardiac pacing, prevent sudden cardiac death, and improve ventricular synchrony in patients with reduced ejection fraction or conduction delays. Technological advancement drives the growth of the market. In March 2025, MicroPort Scientific Corporation gained CE Mark approval for its SmartView Connect App Mobile, allowing Android-based remote monitoring of Bluetooth-enabled pacemakers, ICDs, and CRT-Ds. The app securely transmits encrypted data to the SmartView network, replacing bedside monitors and supporting real-time, clinic-connected cardiac care across Europe.

The cardiac monitoring devices segment is anticipated to grow at the fastest CAGR over the forecast period. Cardiac monitoring devices are designed to continuously or intermittently assess electrical and hemodynamic cardiac parameters, enabling early detection of arrhythmias, ischemia, and other cardiac events. These systems are essential in acute and ambulatory care, supporting diagnosis, treatment planning, and long-term disease management. Key products in this category include Holter monitors, event recorders, mobile cardiac telemetry systems, and ECG machines used in hospitals and outpatient settings. Technological advancement drives the growth of the market. In February 2025, CB Scientific launched its next-generation MyCardia AT cardiac event monitor across Southeast Asia, Hong Kong, and Macau. The FDA-cleared device features a lightweight, user-friendly design with smartphone compatibility, allowing for up to 30 days of remote ECG monitoring. As local distributors begin regulatory approvals, the company aims to scale its connected cardiac monitoring ecosystem and expand its presence in key global markets.

End Use Insights

By end use, the hospital segment dominated the cardiac monitoring and cardiac rhythm management devices market, accounting for a revenue share of 53.43% in 2024. Hospitals remain the primary setting for the use and adoption of cardiac monitoring and cardiac rhythm management (CRM) devices, driven by their ability to handle high-acuity patients and deliver device-based interventions. Key devices include Holter monitors, telemetry systems, event monitors, ECG machines, pacemakers, ICDs, and CRT devices. Hospitals rely on continuous cardiac monitoring for patients in emergency, intensive care, and perioperative settings to detect arrhythmias, ischemic events, or heart failure decompensation early and intervene accordingly. In November 2024, BioIntelliSense reported results from a 15-month study showing that its chest-worn BioButton device reduced hospital stays for cardiac patients from 3.07 to 2.75 days. The wearable provided early warnings of deterioration 14.8 hours in advance, improving clinical response times. The device continuously tracked heart rate, respiration, and other vitals in over 12,000 patients, enabling 114 new or modified physician orders during monitoring.

The ambulatory surgery centers segment is expected to experience significant growth over the forecast period. Ambulatory surgery centers (ASCs) are increasingly involved in the procedural side of cardiac rhythm management, particularly for patients requiring low-risk pacemaker or loop recorder implantation. The shift toward ASCs reflects broader efforts to reduce inpatient burden and procedural costs while maintaining clinical outcomes. These centers typically cater to stable patients and use minimally invasive techniques, supported by portable ECG and device programming tools, to perform device implants and diagnostics with quick turnaround. In February 2024, the American College of Cardiology launched its CV ASC Registry Suite to track the increasing number of cardiac procedures performed in ambulatory surgical centers. The registry tracks interventions such as diagnostic catheterization, pacemaker, and defibrillator implantations, key product types in the cardiac rhythm management and monitoring devices market. It provides benchmarking data that may influence product adoption trends in outpatient cardiac care.

Regional Insights

North America dominated the cardiac monitoring and cardiac rhythm management devices market with a revenue share of 45.64% in 2025. Increased prevalence of atrial fibrillation (AFib) drives the growth of the U.S. cardiac monitoring and cardiac rhythm management devices market. According to the American Heart Association article published in March 2025, Atrial fibrillation (AFib), the most prevalent form of irregular heart rhythm, affected about five million individuals across the U.S. in 2024. Projections indicate this number could surpass 12+ million by 2030, reflecting a significant rise in the burden of arrhythmias nationwide. This growing prevalence is a key factor fueling demand for advanced cardiac monitoring tools and cardiac rhythm management devices in North America.

U.S. Cardiac Monitoring and Cardiac Rhythm Management Devices Market Trends

The U.S. cardiac monitoring and cardiac rhythm management devices industry led North America in 2025. Technologically advanced products launched by key manufacturers drive the market's growth. For instance, in December 2024, HeartBeam, Inc., a medical technology firm dedicated to advancing cardiac care through innovative diagnostic tools, recently announced that it has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its HeartBeam system, designed for comprehensive arrhythmia detection. This marks the first FDA clearance for a device of its kind, featuring a unique, patented approach. The HeartBeam system offers a high-fidelity electrocardiogram (ECG) capability within a compact, credit card-sized, wireless design, enabling the capture of heart activity from three different angles to deliver critical insights into cardiac health.

Europe Cardiac Monitoring and Cardiac Rhythm Management Devices Market Trends

The cardiac monitoring and cardiac rhythm management devices industry in Europe is expected to experience significant growth over the forecast period. The high mortality rate from cardiovascular diseases boosts demand for cardiac monitoring and cardiac rhythm management devices in Europe. According to the WHO article published in May 2024, cardiovascular diseases (CVDs) are the leading cause of disability and premature death in the European Region, responsible for over 42.5% of all deaths annually. This staggering statistic translates to approximately 10,000 deaths every day. The significant impact of CVD emphasizes the urgent need for advanced cardiac monitoring and cardiac rhythm management solutions.

The UK cardiac monitoring and cardiac rhythm management devices market is expected to grow significantly during the forecast period. Growing AFib incidence in the UK drives the growth of the market. According to the British Heart Foundation article published in January 2025, in the UK, over 1.6 million people have been diagnosed with atrial fibrillation (AFib). This communal heart rhythm disorder increases the risk of stroke and other serious complications. Despite many diagnoses, many patients still do not receive optimal treatment or consistent monitoring. This gap in care highlights the urgent need for more advanced solutions to detect, track, and manage AF effectively.

Asia Pacific Cardiac Monitoring and Cardiac Rhythm Management Devices Market Trends

The Asia Pacific cardiac monitoring and cardiac rhythm management devices industry is expected to register the fastest CAGR over the forecast period. Rising elderly population in the Asia Pacific region. According to the United Nations Economic and Social Commission for Asia and the Pacific, in 2023, approximately 697 million individuals aged 60 years or older lived in Asia and the Pacific region, constituting approximately 60% of the global older population. The elderly population is more susceptible to cardiovascular diseases, and the increase in the population is leading to a higher demand for cardiac monitoring and cardiac rhythm management devices.

China's cardiac monitoring and cardiac rhythm management devices market is anticipated to grow considerably during the forecast period. Increasing CVD cases drive the growth of the market. According to an NCBI article published in November 2023, China faces a massive health challenge, with an estimated 330 million people affected by cardiovascular diseases, underscoring the country’s growing burden of heart-related conditions. This vast patient pool is driving demand for advanced cardiac monitoring and rhythm management devices, as healthcare providers seek to enhance early detection, accurate diagnosis, and effective treatment of conditions such as arrhythmias, heart failure, and coronary artery disease.

Latin America Cardiac Monitoring and Cardiac Rhythm Management Devices Market Trends

The Latin America cardiac monitoring and cardiac rhythm management devices industry is anticipated to witness considerable growth over the forecast period, fueled by rising cardiovascular disease incidence, aging populations, and awareness of early diagnosis and preventive care. Countries across the region are increasingly adopting advanced technologies such as implantable monitors, wearable ECG devices, and modern defibrillators to improve patient outcomes. In June 2025, Dong-A ST launched its HiCardi+ remote cardiac monitoring platform in Brazil, introducing a wearable ECG patch connected to a smartphone and entering the Latin American digital health market through a partnership with Cardio Web.

Argentina's cardiac monitoring and cardiac rhythm management devices market is anticipated to register considerable growth during the forecast period. Rising adoption of cardiac rhythm devices drives the development of the market. According to an NCBI article published in December 2024, over 22,000 cardiac rhythm management devices were implanted nationwide in 2022, highlighting the growing reliance on advanced cardiac technologies. Moreover, pacemakers accounted for most of these procedures, with approximately 18,699 units implanted, representing 84.1%. This surge in device utilization reflects the increasing burden of arrhythmias and other heart rhythm disorders, as well as the expanding capacity of Argentina’s healthcare system to adopt life-saving rhythm management solutions.

Middle East & Africa Cardiac Monitoring and Cardiac Rhythm Management Devices Market Trends

The Middle East and Africa cardiac monitoring and cardiac rhythm management devices industry is anticipated to witness considerable growth over the forecast period, driven by rising cases of cardiovascular diseases and arrhythmias, as well as increasing awareness about the benefits of early detection and modern treatments. Countries in the region report higher rates of arrhythmias, heart failure, and other cardiac conditions, prompting a greater demand for technologies that help monitor and regulate heart rhythms. In January 2025, the UAE introduced Biosigns, an FDA-cleared AI tool that uses smartphone facial scanning to measure vital signs, including cholesterol, hemoglobin, heart rate, blood pressure, and stress within seconds. Launched at Arab Health 2025, it is designed to support preventive care and integrate with the country’s unified health record system.

The UAE cardiac monitoring and cardiac rhythm management devices market is anticipated to grow considerably during the forecast period. Increasing CVD mortality drives the growth of the market. According to the American Heart Association, Inc., an article published in November 2024, in the United Arab Emirates, cardiovascular diseases remain the foremost health challenge, responsible for 36.7% of all deaths, emphasizing the significant impact of heart-related conditions on public health. This high burden of disease highlights the urgent need for advanced diagnostic and therapeutic solutions to detect and manage heart rhythm disorders effectively.

Key Cardiac Monitoring and Cardiac Rhythm Management Company Insights

Key participants in the cardiac monitoring and cardiac rhythm management devices industry focus on devising innovative business growth strategies, such as expanding their product portfolios, forming partnerships and collaborations, engaging in mergers and acquisitions, and expanding their business footprints.

Recent Developments

• In December 2025, SMART in Singapore launched WITEC, a program developing a wearable ultrasound patch for real time, long duration cardiovascular monitoring. Supported by MIT, NTU, NUS, and TTSH, the project aims to enable up to 48 hours of continuous imaging for chronic conditions, with clinical trials set to begin in early 2026.

• In December 2025, OMRON Healthcare rolled out a global ECG strategy aimed at boosting early heart-failure detection. The plan includes increased investment in Tricog Health India and the acquisition of the Heartnote ECG service business, along with integrating AI-driven cardiac analytics into its ECG devices to expand remote monitoring and faster diagnosis.

• In December 2025, Chennai-based vTitan launched vCardio, an AI-powered wearable cardiac monitor designed for continuous ECG tracking at home and in clinics. The lightweight patch device pairs with a mobile app and cloud platform, detects over 20 arrhythmias using AI, and supports long-duration remote monitoring to make cardiac screening more accessible.

• In June 2024, Stryker launched the LIFEPAK 35 monitor/defibrillator to support advanced life support in both EMS and hospital settings. The device features an intuitive touchscreen, real-time data connectivity, and ergonomic design. It aims to reduce cognitive burden and improve response efficiency for frontline providers.

• In May 2024, Koninklijke Philips N.V. rolled out its wearable ePatch and AI-powered Cardiologs analytics platform to 14 hospitals across Spain. The solution supports long-term ambulatory cardiac monitoring, enabling the early detection of atrial fibrillation and reducing the burden on emergency rooms. Clinical use at Vall d’Hebron Hospital led to shorter stays and cost savings.

• In April 2024, MicroPort Scientific Corporation launched TALENTIA and ENERGYA, its new Bluetooth-enabled ICD and CRT-D ranges in Europe. These devices offer advanced remote monitoring, MRI compatibility, and the exclusive SonR hemodynamic optimization sensor. A modern tablet programmer interface was also introduced to streamline patient management and follow-up.

Cardiac Monitoring And Cardiac Rhythm Management Devices Market Report Scope

Global Cardiac Monitoring And Cardiac Rhythm Management Devices Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and analyzes the latest trends in each sub-segment from 2021 to 2033. For this report, Grand View Research has segmented the global cardiac monitoring and cardiac rhythm management devices market report based on product, end use, and region:

• Product Outlook (Unit Volume in ‘000 Units; Average Selling Price in USD per Unit; Revenue in USD Million, 2021 - 2033)

  • Cardiac Monitoring Devices​​​​​​​

    • ECG

    • Implantable Cardiac Monitors

    • Holter Monitors

    • Mobile Cardiac Telemetry

  • Cardiac Rhythm Management Devices

    • Pulse Generators

      • Cardiac Resynchronization Therapy (CRT)

        • CRT-Defibrillator

        • CRT-Pacemakers

      • Defibrillators

        • Implantable Cardioverter Defibrillators (ICD)

        • Transvenous Implantable Cardioverter Defibrillators (TIICDs)

          • Single Chamber

          • Dual Chamber

        • Subcutaneous Implantable Cardioverter Defibrillators (S-ICDs)

        • External Defibrillator.

      • Pacemakers

        • Conventional Pacemakers

        • Leadless Pacemakers

    • Leads

      • Pacing Leads

        • Standard RV/LV Leads

        • Conduction System Pacing (CSP) / LBBAP Leads

      • Defibrillator Leads

        • Traditional Leads

        • LV Leads

• End Use Outlook (Revenue USD Million, 2021 - 2033)

  • Hospitals

  • Ambulatory Surgery Centers

  • Others

• Regional Outlook (Unit Volume in ‘000 Units; Average Selling Price in USD per Unit; Revenue in USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait